Goldman Sachs Upgrades Boston Scientific (BSX) to Neutral

Goldman Sachs upgraded Boston Scientific (NYSE: BSX) from Sell to Neutral and raised their price target from $6.50 to $7.

The firm said they no longer see material downside to consensus estimates, and the stock is one of the worst performing S&P healthcare so far this year.

For more ratings news on Boston Scientific click here and for the rating history of Boston Scientific click here.

Shares of Boston Scientific closed at $6.67 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Upgrades Target Hospitality (TH) to Buy
• William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
• JPMorgan Upgrades Nokian Renkaat Oyj (TYRES:FH) (NKRKY) to Neutral